Fisher Asset Management LLC Acquires 46,490 Shares of Takeda Pharmaceutical Co. $TAK

Fisher Asset Management LLC raised its holdings in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 89.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 98,635 shares of the company’s stock after acquiring an additional 46,490 shares during the quarter. Fisher Asset Management LLC’s holdings in Takeda Pharmaceutical were worth $1,525,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of TAK. West Family Investments Inc. lifted its position in Takeda Pharmaceutical by 8.2% during the second quarter. West Family Investments Inc. now owns 36,207 shares of the company’s stock valued at $560,000 after purchasing an additional 2,739 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after buying an additional 1,292 shares during the period. Capital Fund Management S.A. lifted its position in shares of Takeda Pharmaceutical by 216.1% during the 2nd quarter. Capital Fund Management S.A. now owns 126,279 shares of the company’s stock valued at $1,952,000 after buying an additional 86,333 shares in the last quarter. Choreo LLC grew its stake in shares of Takeda Pharmaceutical by 16.6% during the 2nd quarter. Choreo LLC now owns 24,801 shares of the company’s stock valued at $383,000 after acquiring an additional 3,539 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in Takeda Pharmaceutical by 28.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 83,061 shares of the company’s stock worth $1,284,000 after acquiring an additional 18,598 shares in the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Trading Down 0.7%

Takeda Pharmaceutical stock opened at $14.18 on Friday. Takeda Pharmaceutical Co. has a 1 year low of $12.80 and a 1 year high of $15.69. The firm’s 50 day moving average price is $14.11 and its 200-day moving average price is $14.62. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.37 and a quick ratio of 0.76. The stock has a market cap of $45.10 billion, a P/E ratio of 177.19 and a beta of 0.04.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, October 30th. The company reported $0.44 earnings per share for the quarter, meeting the consensus estimate of $0.44. The company had revenue of $7.30 billion during the quarter, compared to analysts’ expectations of $8.01 billion. Takeda Pharmaceutical had a net margin of 0.86% and a return on equity of 10.32%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. On average, equities analysts predict that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TAK has been the subject of a number of recent analyst reports. Zacks Research lowered shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 21st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.